Theriva Biologics (TOVX) announced that the company had become aware of unusual trading activity in its common stock on the NYSE American on October 24. “The company has made inquiries and does not believe corrective actions are appropriate. The company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action. However, on October 13, 2025, the company announced the presentation of expanded data from its VIRAGE trial investigating VCN-01 at a mini oral session at the European Society for Medical Oncology Annual Congress,” the company stated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Presents Promising Phase 2b Trial Data
- Theriva Biologics Secures $4M Through Warrant Agreement
- Theriva Biologics announces warrant inducement transaction for $4M in proceeds
- Theriva Biologics Presents Promising VCN-12 Preclinical Data
- Theriva Biologics Unveils VCN-12 Preclinical Data